| Date | Title | Description | Source |
| 08.01.2024 | This is the TLDR of JPM Day 1 | In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To st... | statnews.c... |
| 16.07.2023 | The Next Frontier For Large Language Models Is Biology | David Baker (University of Washington), Demis Hassabis (DeepMind) and George Church (Harvard) have .... | forbes.com... |
| 10.05.2023 | 16 top healthcare bankers and dealmakers reveal their predic... | Barclays; Lazard; Canaccord Genuity; General Atlantic; Insider This story is available exclusively t... | businessin... |
| 14.03.2023 | The delisting dilemma: Why do so many biotechs face being ki... | The latest fear stalking biotech boardrooms isn’t a trial fail or an underwhelming funding haul, it’... | fiercebiot... |
| 03.03.2023 | Big Pharma regained 'mojo' last year, but biotech valuations... | Anyone looking for a road map out of the biotech bear market will take little comfort from Evaluate ... | fiercebiot... |
| 19.01.2023 | EQRx promised to deliver cutting-edge drugs at half the cost... | EQRx cofounder and executive chairman Alexis Borisy EQRx This story is available exclusively to Insi... | businessin... |
| 04.01.2023 | Biotech investor Brad Loncar shares 10 predictions for 2023,... | Brad Loncar, biotech investor and CEO of Loncar Investments Brad Loncar This story is available excl... | businessin... |
| 20.11.2022 | Acrivon Nets $100M for Protein Tech That Picks Patients for ... | For targeted cancer therapy to work, it’s not enough to identify the right targets to hit with a dru... | medcitynew... |
| 04.11.2022 | FDA delays decision for Apellis' eye disease drug afte... | Apellis had secured a priority review for its geographic atrophy program, but it turns o... | endpts.com... |
| 01.11.2022 | Betting on CD47 as others ditch the target, ALX borrows ... | At its peak, ALX Oncology $ALXO was trading at $88 per share, riding on the promise of blockin... | endpts.com... |
| 25.10.2022 | FDA approves J&J's BCMA-targeted bispecific for m... | The FDA on Tuesday granted accelerated approval to Johnson & Johnson’s Tecvayli (tecli... | endpts.com... |
| 18.10.2022 | Evaluate Forecasts Pharmaceutical Market to be Worth $1.6tn ... | New World Preview report finds strong top-line growth as pricing and patent headwinds build
London,... | realwire.c... |
| 07.09.2022 | Congress should not compel Medicare to pay for liquid biopsi... | When the two Republican senators from Mississippi cosponsor legislation with the two Democratic sena... | statnews.c... |
| 19.07.2022 | How To Raise The Bar And Overcome Barriers In The Digital He... | VP Product-Marketing at Itamar-Medical | Digital Health Expert | Business Growth Mentor | mHealth Is... | forbes.com... |
| 28.06.2022 | Citeline and Norstella Unite to Offer Life Sciences Clients ... | The new organization will help life sciences companies improve strategic decision-making and acceler... | realwire.c... |
| 17.06.2022 | Pushing for top spot in Big Pharma, AbbVie lands a key a... | AbbVie just scored another win in its campaign to make Skyrizi one of the top blockbusters in ... | endpts.com... |
| 11.05.2022 | Evaluate appoints Matthew Wright as Chief Financial Officer | London, UK and Boston, MA – 11 May 2022 – Evaluate, a leading provider of market intelligence and pr... | realwire.c... |
| 28.04.2022 | Evaluate report signals orphan drug market is niche no more | London, UK – 28 April 2022 – Evaluate, the leading provider of market intelligence and predictive an... | realwire.c... |
| 25.04.2022 | After 18 years in development, AstraZeneca’s CTLA-4 an... | After a decade, a second CTLA-4 antibody may finally be on its way to approval.
AstraZenec... | endpts.com... |
| 21.04.2022 | Evaluate announces global strategic collaboration with Treeh... | London, UK and New York, USA – 21 April 2022 – Evaluate and Treehill Partners today announced that t... | realwire.c... |
| 21.03.2022 | Medtech's top 10 money raisers of 2021 | The medtech industry’s impressive venture funding activity was an anomaly in 2020, when most other s... | fiercebiot... |
| 01.03.2022 | FDA rejects Gilead’s next big HIV drug over glass vial issue... | Gilead on Tuesday received a rejection letter for its latest potential first-in-class HIV drug, as t... | endpts.com... |
| 18.02.2022 | After selling off Tibsovo and entire cancer pipeline, Agios ... | Agios’ long-term plan is starting to come into focus, as the biotech won its first FDA approval sinc... | endpts.com... |
| 03.02.2022 | Roche regains pre-pandemic sales footing, highlights burstin... | While many pharma fortunes are tied to Covid-19 pandemic peaks and valleys, Roche’s connections are ... | endpts.com... |
| 26.01.2022 | CytoDyn fires embattled CEO as its growing chorus of c... | The annual exercise where analysts try and predict which drugs will become blockbusters and make the... | endpts.com... |
| 14.01.2022 | Vir expands partnership with Gates Foundation, adding $... | Just two days after the US bought 600,000 more doses of Vir and GSK’s Covid-19 antibody sotrovi... | endpts.com... |
| 14.01.2022 | After nabbing two AI-generated molecules, AstraZenec... | Roughly three years ago, AstraZeneca teamed up with London’s BenevolentAI to bring new drugs i... | endpts.com... |
| 13.01.2022 | Exclusive: Biogen leaders warn sales teams: Only 2,000 ... | Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in yo... | endpts.com... |
| 13.01.2022 | Exclusive: Biogen leaders warn sales teams: Only 2,000 ... | While 2021 was another big year for biopharma R&D — with the number of IPOs and biotech VC fundi... | endpts.com... |
| 20.12.2021 | FDA hands AstraZeneca-Amgen broad approval for asthma an... | After last year’s Phase III results, there was little question that the FDA would approve Amge... | endpts.com... |
| 13.12.2021 | The top 10 M&A targets in medtech for 2022 | As was to be expected, mergers and acquisitions in the medtech sector slowed down quite a bit in the... | fiercebiot... |
| 18.11.2021 | Novo Nordisk reaches $3.3B deal to acquire RNAi partner Dice... | The field of RNA interference therapies is bustling with activity and Novo Nordisk is the latest com... | medcitynew... |
| 12.11.2021 | Cardinal Health : Balancing the Needs of Today with the Oppo... | Balancing the Needs of Today with the Opportunities of Tomorrow
11/10/2021
By Heidi Hunter, Presid... | marketscre... |
| 20.10.2021 | Blood tests that can detect cancer are about to hit the mark... | A scientist drips blood into a test tube. Serhii Hudak/ Ukrinform/Barcroft Media via Getty Images
T... | businessin... |
| 09.09.2021 | Apellis turns up mixed results in closely watched eye dis... | Looking to scuffle with rare disease giant and now AstraZeneca subsidiary Alexion, little Ap... | endpts.com... |
| 03.08.2021 | Rare disease drugmakers to Congress: Don't gut the acce... | The controversy over the FDA’s accelerated approval pathway is heating up.
Last week, the... | endpts.com... |
| 02.08.2021 | Stifling biopharma mergers would kill the innovation economy... | The headlines speak of a biotech boom with news of company launches, oversubscribed private financin... | statnews.c... |
| 14.07.2021 | AstraZeneca's planned takeover of Alexion clears last reg... | The final regulatory hurdle for AstraZeneca’s mega-merger with Alexion Pharmaceuticals ... | endpts.com... |
| 09.07.2021 | Bayer takes SGLT2 hopefuls head on with FDA approval for ... | The FDA on Friday approved Bayer Pharmaceuticals’ chronic kidney disease drug Kerendia (f... | endpts.com... |
| 18.05.2021 | AbbVie is facing the biggest challenge yet to its best-selli... | AbbVie CEO Richard A. Gonzalez. AP Photo/Pablo Martinez Monsivais This story is available exclusivel... | businessin... |
| 17.05.2021 | The top 10 medtech VC rounds of 2020 | Last year, the COVID-19 pandemic sent countless businesses and entire industries around the world in... | fiercebiot... |
| 10.05.2021 | Bayer claims another win on its CKD and diabetes hopef... | After earning priority review for a top CKD and diabetes program back in January, Bayer ... | endpts.com... |
| 22.03.2021 | Biotech's top 10 money raisers of 2020 | As the coronavirus started to spread in 2020, industry watchers hoped the biopharma sector would pul... | fiercebiot... |
| 13.02.2021 | Another Keytruda combo tops standard of care in advanc... | Every company on this list of the top 10 2019 marketing launches — compiled by Evaluate in January —... | endpts.com... |
| 04.11.2020 | This fintech startup helps investors evaluate the impact of ... | Over the past decade, impact investing has gained significant momentum as both an investment strateg... | siliconcan... |
| 27.10.2020 | An evolution in early stage gene therapy funding models | A tsunami of curative gene therapies for rare diseases will get through pivotal trials in the coming... | ucltf.co.u... |
| 15.10.2020 | News briefing: Otsuka’s $886M cancer drug is now a 3-tim... | Two years after Otsuka unveiled a flop in their first Phase III trial of guadecitabine as a fro... | endpts.com... |
| 09.09.2020 | Dabbling in CD47, Pfizer infuses $25M into a biotech pl... | Pfizer is following Gilead, AbbVie, Boehringer and a string of biotech upstarts into the CD47... | endpts.com... |
| 20.08.2020 | Watch out Bristol Myers, Merck is right on your heels wit... | Merck announced positive Phase III results to back yet another indication for cash cow Key... | endpts.com... |
| 19.08.2020 | Another blow to NASH, disappointing trial results spe... | Another NASH program is headed to the scrap heap.
Albireo $ALBO, a Boston biotech that took a... | endpts.com... |
| 14.08.2020 | TRIFAST PLC
Trifast : 2020 Annual Report | Annual Report for the year ended 31 March 2020
Our fastenings enable innovation today
to build a b... | marketscre... |
| 06.04.2020 | Top biotech money raisers of 2019 | At first glance, venture investment for biotech slumped in 2019. By the raw numbers, 2019 lost on ev... | fiercebiot... |
| 01.04.2020 | Evaluate Acquires Black Swan Analysis | Evaluate Ltd., a London, UK-based provider of commercial intelligence and predictive analytics to th... | finsmes.co... |
| 13.03.2020 | Mending the broken social contract for pharmaceutical pricin... | The biopharmaceutical industry is under unprecedented assault by the public and politicians. Hostili... | statnews.c... |
| 03.09.2019 | ESC Congress 2019: Biotronik beats Abbott at target lesion f... | Biotronik said yesterday that its Orsiro stent tops the Xience stents made by Abbott (NYSE:ABT) when... | massdevice... |
| 03.09.2019 | Armed with promising alopecia PhII, Concert edges forwar... | Concert Pharma has scored a fresh round of positive Phase II data for its JAK inhibitor amid a... | endpts.com... |
| 31.07.2019 | Report: “Unglamorous” medtech outshines biopharma in 2019... | Medtech merger and acquisition deal announcements slowed in the first half of 2019, but the industry... | massdevice... |
| 24.05.2019 | Why precision medicines for oncology demands precision engag... | Life sciences companies are overwhelmed with the volume of information and data available as they ai... | medcitynew... |
| 15.05.2019 | Biotech's top 10 money raisers of 2018 | If 2017 was a banner year for biotech venture capital, 2018 blew it out of the water. Last year, pri... | fiercebiot... |
| 01.04.2019 | Atlas wraps Arteaus story with $260M royalty sale as Em... | Six months after Eli Lilly notched a second-runner-up approval for its CGRP migraine drug Emg... | endpts.com... |
| 22.01.2019 | Celgene, sold for $74 billion, leaves a legacy of chutzpah i... | Nina Kjellson was just two years out of college, working as a research associate at Oracle Partners,... | statnews.c... |
| 14.11.2018 | Exclusive: Digital health company HeartFlow gets Japanese re... | The company claims that using its technology allows doctors to make more cost-efficient and safer cl... | medcitynew... |
| 25.09.2018 | Carillon hits the right note | Vantage
by Elizabeth Cairns
25 September 2018
Abbott’s MitraClip is suddenly hot property after the... | mhcarnegie... |
| 05.09.2018 | What's up at Immunocore?; Pfizer nabs a key 'breakthroug... | → What’s up at Immunocore? Vantage is reporting that Immunocore’s chief strategy officer ... | endpts.com... |
| 10.08.2017 | In an era of mega-rounds, Roivant Sciences still makes a spl... | Announced Wednesday, the company said the new capital injection is designed to “accelerate the launc... | medcitynew... |
| 29.10.2016 | Cognitive assessment startup using games to evaluate brain f... | BrainCheck is a participant in the Texas Medical Center Accelerator in Houston. The company’s backer... | medcitynew... |
| - | Why precision medicines for oncology demands precision engag... | The speed of scientific breakthroughs in precision medicine is leading to groundbreaking treatments,... | medcitynew... |
| - | Microbiome biotech Kaleido Biosciences shutters amid cash cr... | Microbiome therapies could have a big year as several biotech companies are preparing for key regula... | medcitynew... |
| - | Here are the 18 investors set to shape biotech in 2022 | This story is available exclusively to Insider subscribers. Become an Insider and start reading now.... | businessin... |
| - | The DNA of better health care for rare diseases | Less than two decades into the genomic era in health care, our knowledge about the connections betwe... | statnews.c... |
| - | Cognitive assessment startup using games to evaluate brain f... | BrainCheck cognitive assessment test
BrainCheck, a Houston-based health IT company that digitized c... | medcitynew... |
| - | Evaluate Vision: harnessing data science to quantify technic... | created February 2020
London’s Evaluate absorbs, aggregates, structures, normalises and enriches th... | hgcapital.... |
| - | Novo Nordisk reaches $3.3B deal to acquire RNAi partner Dice... | The field of RNA interference therapies is bustling with activity and Novo Nordisk is the latest com... | medcitynew... |
| - | In an era of mega-rounds, Roivant Sciences still makes a spl... | The top drug recycling engine in the game, Roivant Sciences, has raised a massive $1.1 billion equit... | medcitynew... |
| - | Exclusive: Digital health company HeartFlow gets Japanese re... | Redwood City, California-based digital health company HeartFlow has reached a major milestone in its... | medcitynew... |
